{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T22:42:45Z","timestamp":1778107365827,"version":"3.51.4"},"reference-count":30,"publisher":"European Respiratory Society (ERS)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2012,1,8]]},"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:p>Current guidelines recommend adding a long-acting inhaled \u03b2<jats:sub>2<\/jats:sub>-agonist (LABA) to inhaled corticosteroids (ICS) in patients with uncontrolled asthma. This study evaluated the novel, once-daily LABA vilanterol trifenatate (VI) in asthma patients who remained symptomatic despite existing ICS therapy.<\/jats:p><jats:p>The study involved a randomised, double-blind, placebo-controlled trial of VI (3, 6.25, 12.5, 25 and 50 \u03bcg), administered once daily in the evening by dry powder inhaler for 28 days, in asthma patients aged \u226512 yrs symptomatic on current ICS therapy. The primary end-point was trough (24 h post-dose) forced expiratory volume in 1 s (FEV<jats:sub>1<\/jats:sub>); secondary end-points were weighted mean FEV<jats:sub>1<\/jats:sub>, peak expiratory flow (PEF), symptom-\/rescue-free 24-h periods, and safety.<\/jats:p><jats:p>A significant relationship was observed between VI dose and improvements in trough FEV<jats:sub>1<\/jats:sub>(p=0.037). Statistically significant increases in mean trough FEV<jats:sub>1<\/jats:sub>, relative to placebo, were documented for VI 12.5\u201350 \u03bcg (121\u2013162 mL; p\u22640.016). Dose-related effects of VI were observed on weighted mean (0\u201324 h) FEV<jats:sub>1<\/jats:sub>, morning\/evening PEF, and symptom-\/rescue-free 24-h periods. All doses of VI were well tolerated with low incidences of recognised LABA-related adverse events (tremor 0\u20132%; palpitations 0\u20132%; glucose effects 0\u20131%; potassium effects 0\u2013&lt;1%).<\/jats:p><jats:p>Once-daily VI 12.5\u201350 \u03bcg resulted in prolonged bronchodilation of at least 24 h with good tolerability in asthma patients receiving ICS. Based on the overall efficacy and adverse event profile from this study, the optimum dose of VI appears to be 25 \u03bcg.<\/jats:p>","DOI":"10.1183\/09031936.00121411","type":"journal-article","created":{"date-parts":[[2012,2,24]],"date-time":"2012-02-24T03:59:04Z","timestamp":1330055944000},"page":"570-579","source":"Crossref","is-referenced-by-count":64,"title":["24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids"],"prefix":"10.1183","volume":"40","author":[{"given":"Jan","family":"L\u00f6tvall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric D.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene R.","family":"Bleecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William W.","family":"Busse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Woodcock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Follows","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loretta","family":"Jacques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett","family":"Haumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2012,2,23]]},"reference":[{"key":"2024102021020185000_40.3.570.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200102013440507"},{"key":"2024102021020185000_40.3.570.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11312-2"},{"key":"2024102021020185000_40.3.570.3","unstructured":"Global Initiative for Asthma(GINA). lobal Strategy for Asthma Management and Prevention. www.ginasthma.org. Date last accessed: July 1, 2011. Date last updated: December 2010."},{"key":"2024102021020185000_40.3.570.4","doi-asserted-by":"publisher","DOI":"10.3109\/02770900903184237"},{"key":"2024102021020185000_40.3.570.5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200401-033OC"},{"key":"2024102021020185000_40.3.570.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.02.031"},{"key":"2024102021020185000_40.3.570.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ambp.2006.11.007"},{"key":"2024102021020185000_40.3.570.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2006.09.017"},{"key":"2024102021020185000_40.3.570.9","first-page":"CD005535","article-title":"Addition of long-acting \u03b22-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children","volume":"5","author":"Ducharme","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2024102021020185000_40.3.570.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199711133372001"},{"key":"2024102021020185000_40.3.570.11","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2004.039180"},{"key":"2024102021020185000_40.3.570.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.01.013"},{"key":"2024102021020185000_40.3.570.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.10.011"},{"key":"2024102021020185000_40.3.570.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2010.02414.x"},{"key":"2024102021020185000_40.3.570.15","first-page":"A4453","article-title":"Pharmacological characterisation of GW642444, a long-acting \u03b22-agonist (LABA) with rapid onset and long duration, on isolated large and small human airways","volume":"181","author":"Barrett","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102021020185000_40.3.570.16","first-page":"A4451","article-title":"In vitro pharmacological characterisation of GW642444, a novel long acting \u03b22-agonist using human recombinant \u03b21\/2\/3 adrenoceptor cAMP assays","volume":"181","author":"Barrett","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl. S4","key":"2024102021020185000_40.3.570.17","first-page":"1013s","article-title":"Dose-related efficacy of vilanterol trifenatate (VI), a long-acting \u03b22 agonist (LABA) with inherent 24-hour activity, in patients with persistent asthma","volume":"36","author":"L\u00f6tvall","year":"2010","journal-title":"Eur Respi J"},{"key":"2024102021020185000_40.3.570.18","first-page":"A4491","article-title":"Four weeks' treatment with the novel long-acting \u03b22 agonist (LABA) vilanterol trifenatate (VI) in asthma \u2013 evaluation of safety and maintained efficacy of albuterol","volume":"183","author":"L\u00f6tvall","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102021020185000_40.3.570.19","unstructured":"National Institutes of Health. Guidelines for the Diagnosis and Management of Asthma (EPR-3) 2007. Bethesda, NHLBI, 2007."},{"key":"2024102021020185000_40.3.570.20","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.159.1.9712108"},{"key":"2024102021020185000_40.3.570.21","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-12-132"},{"key":"2024102021020185000_40.3.570.22","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1164\/ajrccm\/147.6_Pt_1.1436","article-title":"Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma","volume":"147","author":"Rabe","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"2024102021020185000_40.3.570.23","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-7-110"},{"key":"2024102021020185000_40.3.570.24","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2010.31.3309"},{"key":"2024102021020185000_40.3.570.25","doi-asserted-by":"publisher","DOI":"10.3109\/02770900903556439"},{"key":"2024102021020185000_40.3.570.26","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.116608"},{"key":"2024102021020185000_40.3.570.27","doi-asserted-by":"publisher","DOI":"10.1136\/thx.43.9.674"},{"key":"2024102021020185000_40.3.570.28","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.97.10112489"},{"key":"2024102021020185000_40.3.570.29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3109\/02770908609073179","article-title":"Chronobiology and asthma. I. Day-night differences in bronchial patency and dyspnea and circadian rhythm dependencies","volume":"23","author":"Smolensky","year":"1986","journal-title":"J Asthma"},{"key":"2024102021020185000_40.3.570.30","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1164\/ajrccm\/147.6_Pt_2.S25","article-title":"Nocturnal asthma: circadian rhythms and therapeutic interventions","volume":"147","author":"Martin","year":"1993","journal-title":"Am Rev Respir Dis"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/09031936.00121411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T06:35:40Z","timestamp":1740378940000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/09031936.00121411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,23]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,8,31]]},"published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1183\/09031936.00121411"],"URL":"https:\/\/doi.org\/10.1183\/09031936.00121411","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,23]]}}}